CompletedNot Applicable

Antithrombotic Strategies in Coronary Artery Dilatations and Aneurysms

France51 participantsStarted 2024-09-06

Plain-language summary

Objectives: The discovery of aneurysmal or ectatic lesions of the coronary arteries during coronary angiography or coronary CT angiography poses a triple challenge in terms of aetiology, treatment and prognosis. The aim of this study, based on coronary angiograms performed over a 10-year period at the Centre Hospitalier de Versailles, was to determine which antithrombotic treatment was routinely prescribed to patients with ACC or AEC, the evolution of this long-term treatment, and to analyse the association between the presence/absence of anticoagulant treatment and the rates of ischaemic cardiovascular events and haemorrhagic complications. Materials and methods: This is a non-interventional, observational, single-centre study conducted at the Versailles Hospital Centre from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, living or deceased, hospitalised in the cardiology department who underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient \> 18 years old * Patient living or deceased * Patient with aneurysmal or ectatic coronary artery disease with bi- or tri-truncular involvement at coronary angiography. Exclusion Criteria: * Patient \< 18 years old * Monotruncal aneurysmal or ectatic disease * Absence of coronary aneurysm / ectasia * Patient's opposition to participation in research

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date

Timeframe: Treatment on discharge from hospital and follow-up treatment beween 2013 and 2023

The nature of antithrombotic treatments

Timeframe: Discharge from hospital (day 1)

Trial details

NCT IDNCT07211854

SponsorFranck Assayag

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-09-11

View on ClinicalTrials.gov More Coronary Artery Dilatations and Aneursyms trials